temsirolimus
temsirolimus: 7 clinical trials tracked.
temsirolimus evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about temsirolimus, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Clinical Trials (7)
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas
Primary endpoint: Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial
Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Primary endpoint: Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
Primary endpoint: Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Primary endpoint: Maximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT)
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Primary endpoint: Objective Response
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors
Primary endpoint: Safety and tolerability of twice daily oral doses of AZD6244 when administered in combination with standard doses of selected chemotherapies.